Oxana Denisova receives 30 000 grant from Aamu foundation
Oxana Denisova receives 30 000 grant from Aamu foundation for her research on ‘PP2A in medulloblastoma therapy resistance: novel opportunities for targeted therapeutics.’
– My current research interest belongs to a field of brain cancer resistance and anticancer therapy development, particularly I focus on a role of protein phosphatase 2A (PP2A) and its inhibitor proteins in glioblastoma and pediatric medulloblastoma. I recently demonstrated that combination of PP2A reactivation and multi-kinase inhibition results in profound synergistic cell killing of adult glioblastoma and medulloblastoma cells, Oxana tells.
Recent Posts
- Dissertation Defence: Eleftheria MaranouMSc Eleftheria Maranou, from affiliated MIORG group, succesfully defended the dissertation in Immunology titled “The Achilles’ heel of Read moreSeptember 1, 2026
- Researchers discover molecular mechanism that helps aggressive colorectal cancer to spreadResearchers from the University of Turku in Finland, Turku Bioscience Centre and Gustave Roussy Institute Read moreAugust 25, 2026
- The Novo Nordisk Foundation has awarded funding of approximately one million euros to a research project led by Professor Jukka WestermarckThe Novo Nordisk Foundation has awarded funding of approximately one million euros to a research Read moreAugust 21, 2026
- Early-career researchers invited to BioCity Pre-Symposium on 26 August.Doctoral researchers at BioCity Turku are organising a pre-symposium on 26 August 2026, offering early-career Read moreApril 30, 2026
- 35th BioCity Symposium is arranged 27–28 August 2026.This year, BioCity Symposium is arranged on-site in Mauno Koivisto Centre, BioCity in 27–28 August Read moreApril 14, 2026
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026